{"groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.\n\nBiospecimen Collection: Undergo peripheral blood collection\n\nComputed Tomography: Undergo PET/CT or CT scan\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFilgrastim: Given SC or IV\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV\n\nPegfilgrastim: Given SC\n\nPositron Emission Tomography: Undergo PET/CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies\n\nRadiation Therapy: Receive radiation therapy\n\nVinblastine Sulfate: Given IV","id":"FG000","title":"Arm I (Chemotherapy, Nivolumab, Radiation)"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.\n\nBiospecimen Collection: Undergo peripheral blood collection\n\nBrentuximab Vedotin: Given IV\n\nComputed Tomography: Undergo PET/CT or CT scan\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFilgrastim: Given SC or IV\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPegfilgrastim: Given SC\n\nPositron Emission Tomography: Undergo PET/CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies\n\nRadiation Therapy: Receive radiation therapy\n\nVinblastine Sulfate: Given IV","id":"FG001","title":"Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"13"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"9"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"8"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"}],"type":"not protocol specified"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"15"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"496"},{"groupId":"FG001","numSubjects":"498"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"450"},{"groupId":"FG001","numSubjects":"425"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"73"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}